BW-20507
/ Argo Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
January 16, 2026
HBV: A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B
(clinicaltrials.gov)
- P2 | N=209 | Active, not recruiting | Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Hepatitis B • Infectious Disease • Inflammation
November 26, 2025
HBV: A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B
(clinicaltrials.gov)
- P2 | N=200 | Recruiting | Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hepatitis B • Infectious Disease • Inflammation
August 23, 2025
HBV: A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B
(clinicaltrials.gov)
- P2 | N=200 | Not yet recruiting | Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.
New P2 trial • Hepatitis B • Infectious Disease • Inflammation
April 09, 2025
Safety, tolerability, and remarkable hepatitis B surface antigen reduction in chronic hepatitis B patients treated with BW-20507
(EASL 2025)
- "Three subcutaneous doses of BW-20507 were well tolerated and demonstrated a favourable safety profile in patients with CHB. Significant dose-dependent HBsAg reductions have been observed. BW-20507 also has high potency in decreasing HBV DNA."
Clinical • Late-breaking abstract • Fibrosis • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Cirrhosis
April 11, 2025
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic Hepatitis B Virus (HBV) Infection
(ANZCTR)
- P1/2 | N=32 | Active, not recruiting | Sponsor: Argo Biopharma Australia Pty Ltd | Recruiting ➔ Active, not recruiting
Enrollment closed • Hepatitis B • Hepatology • Infectious Disease • Inflammation
February 14, 2025
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects
(ANZCTR)
- P1/2 | N=32 | Completed | Sponsor: Argo Biopharma Australia Pty Ltd | Recruiting ➔ Completed
Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation
December 01, 2023
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic Hepatitis B Virus (HBV) Infection
(ANZCTR)
- P1/2 | N=32 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd
New P1/2 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation
December 01, 2023
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects
(ANZCTR)
- P1/2 | N=32 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd
New P1/2 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation
September 13, 2023
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic Hepatitis B Virus (HBV) Infection
(ANZCTR)
- P1/2 | N=32 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Trial initiation date • Hepatitis B • Hepatology • Infectious Disease • Inflammation
September 13, 2023
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects
(ANZCTR)
- P1/2 | N=32 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Trial initiation date • Hepatitis B • Hepatology • Infectious Disease • Inflammation
1 to 10
Of
10
Go to page
1